Pipeline Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine BioPharma DiveThe startup is developing modified DNA therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy.PipelineGene Therapy PlatformRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) BioPharma Dive The startup is developing modified DNA therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. PipelineGene Therapy PlatformRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA kicks off review of Roche’s Gazyva for wider lupus useNext: The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground Related Stories Pipeline Sanofi drops two more programmes in R&D clear-out pharminent July 30, 2026 Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026 Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026
